Trillium Asset Management LLC lessened its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 2.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 203,221 shares of the company’s stock after selling 5,750 shares during the period. AstraZeneca accounts for 1.0% of Trillium Asset Management LLC’s holdings, making the stock its 20th biggest holding. Trillium Asset Management LLC’s holdings in AstraZeneca were worth $32,846,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Optas LLC lifted its stake in shares of AstraZeneca by 1.5% in the 3rd quarter. Optas LLC now owns 6,959 shares of the company’s stock valued at $1,124,000 after purchasing an additional 100 shares during the period. Phoenix Financial Ltd. grew its stake in AstraZeneca by 21.1% during the third quarter. Phoenix Financial Ltd. now owns 23,453 shares of the company’s stock worth $3,787,000 after purchasing an additional 4,088 shares during the period. Channel Wealth LLC grew its stake in AstraZeneca by 2.8% during the third quarter. Channel Wealth LLC now owns 18,324 shares of the company’s stock worth $2,959,000 after purchasing an additional 501 shares during the period. Hamel Associates Inc. acquired a new stake in AstraZeneca during the third quarter worth approximately $646,000. Finally, Moors & Cabot Inc. bought a new stake in AstraZeneca in the third quarter worth approximately $1,155,000. Institutional investors and hedge funds own 20.35% of the company’s stock.
AstraZeneca Stock Up 0.2%
Shares of AZN stock traded up $0.28 during trading hours on Friday, reaching $184.66. The company had a trading volume of 1,849,945 shares, compared to its average volume of 3,101,796. The business has a fifty day simple moving average of $168.82 and a 200-day simple moving average of $180.20. AstraZeneca Plc has a 12 month low of $153.41 and a 12 month high of $212.71. The company has a market cap of $286.40 billion, a price-to-earnings ratio of 26.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on the company. Wall Street Zen raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Nordea Equity Research raised shares of AstraZeneca from a “sell” rating to a “buy” rating in a research report on Tuesday, October 13th. Weiss Ratings raised shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Finally, CICC Research began coverage on shares of AstraZeneca in a research note on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target for the company. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average price target of $206.67.
Get Our Latest Analysis on AZN
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Further Reading
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
